Emerging therapeutic approaches in renal cell carcinoma.

摘要: In the past decade, targeted therapy with VEGF and mTOR inhibition has significantly improved outcome of renal cell carcinoma. However, management metastatic carcinoma still remains challenging as most patients eventually progress on therapy, long-term survivors are relatively uncommon. There recently been a resurgence interest in cancer immunotherapy development checkpoint inhibitors. Here we discuss best methods to optimize current standard care describe select emerging therapies immunotherapies anti programmed death-1 pathway inhibitors